India Globalization Capital’s CEO to Speak at CEO Healthcare Symposium in NY on February 12 & 13

BETHESDA, Md., Feb. 12, 2018 --

India Globalization Capital, Inc. (NYSE-MKT:IGC) announced today that Ram Mukunda will be a speaker at the upcoming CEO Healthcare Symposium in New York on February 12 and February 13, 2018.  His presentation will include commentary on the Company’s efforts in developing and commercializing cannabis–based pharmaceuticals including Hyalolex for Alzheimer’s disease.

2018 Key Objectives

“We are preparing the groundwork necessary to prepare Hyalolex, our lead product formulation for Alzheimer’s ready for Phase 2-B human trials. Independent of this, we expect to make the product available through medical dispensaries in select states of the U.S. In addition, we are working on addressing issues specific to the medical cannabis industry such as transactional difficulties, inadequate product labeling, product identification assurance (PIA) and product origin assurance (POA), using distributed ledgers inherent in blockchain technology.  We look forward to an exciting 2018 and I wish to thank YJP for the opportunity to speak at their CEO Healthcare Symposium alongside prestigious leaders and innovators in the healthcare industry,” commented Ram Mukunda, CEO.

About the CEO Healthcare Symposium
This event, sponsored by YJP (www.yjp.org) will feature speakers from the hospital, insurance, biotech, pharma, medical device, medtech, senior living, and home care sectors and will bring together top executives from across the healthcare spectrum to discuss the current and future market trends that we are seeing in the industry. 

About Alzheimer’s disease
Alzheimer’s Disease (AD) is a form of dementia.  It is known as America’s most expensive disease, with an estimated cost to the U.S. economy of $236 billion.  AD currently affects more than 5.3 million Americans and over 65% of AD patients are women.  Over the next 20 years, the number of those afflicted with the disease is expected to double.  The forecast is staggering, considering that to date, no effective cure has been found.

About IGC
IGC has two lines of business, a legacy infrastructure business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients. The Company recently announced that it is working on using blockchain to address issues specific to the cannabis industry that address transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA).  The company is based in Maryland, USA.

For more information please visit www.igcpharma.com
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/ 

Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC's Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact:
Claudia Grimaldi
301-983-0998